Gout – management of a chronic disease: a systematic review

1. Tang SCW. Uric Acid in Chronic Kidney Disease Gout: A Disease of Kings. Contrib Nephrol. Basel, Karger. 2018; 192:77-81.10.1159/00048428129393108Search in Google Scholar

2. Richette P, Doherty M, Pascual E et al. 2018 updated European League Against Rheumatism based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020; 79(1):31-38.10.1136/annrheumdis-2019-21531531167758Search in Google Scholar

3. Abhishek A, Roddy AE, Doherty M. Gout – a guide for the general and acute physicians. Clinical Medicine. 2017; 17(1):54-59.10.7861/clinmedicine.17-1-54629758028148582Search in Google Scholar

4. Coburn BW, Mikuls TR. The Problem with Gout Is That It’s Still Such a Problem. J Rheumatol. 2016; 43(8):8-11.Search in Google Scholar

5. Hui M, Carr A, Cameron S et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology. 2017; 56(7):e1–e20,6.10.1093/rheumatology/kex15628549177Search in Google Scholar

6. Michael P, Bs MPR, Monjazeb S, Goodwin BP, Group AR. Ulcerated tophaceous gout. 2019:0-3. Dermatol Online J. 2019; 25(3):1-3.Search in Google Scholar

7. Hainer BL, Matheson E, Wilkes RT. Diagnosis, Treatment, and Prevention of Gout. Am Fam Physician. 2014; 90(12):831-836.Search in Google Scholar

8. Singh JA. Racial and Gender Disparities in Patients with Gout. Curr Rheumatol Rep. 2013; 15(2):1-15.10.1007/s11926-012-0307-x354540223315156Search in Google Scholar

9. Pittman JR, Pharm D, Bross MH. Diagnosis and Management of Gout. Am Fam Physician. 1999; 59(7):1799-1806.Search in Google Scholar

10. Scirè CA, Manara M, Cimmino MA et al. Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther. 2013; 15(5):R101.10.1186/ar4281397909524004577Search in Google Scholar

11. Yu KH, Luo SF, Liou LB et al. Concomitant Septic and Gouty Arthritis-An Analysis of 30 Cases. 2 Rheumatology (Oxford). 2003; 42(9):1062-6.10.1093/rheumatology/keg29712730521Search in Google Scholar

12. Moi JHY, Sriranganathan MK, Falzon L et al. Lifestyle Interventions for the Treatment of Gout: A Summary of 2 Cochrane Systematic Reviews. J Rheumatol Suppl. 2014; 92:26-32.10.3899/jrheum.14045925180125Search in Google Scholar

13. Kuo C, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015; 74:661–667.10.1136/annrheumdis-2013-204463439230724431399Search in Google Scholar

14. Khanna D, Fitzgerald JD, Khanna PP et al. 2012 American College of Rheumatology Guidelines for Management of Gout Part I: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. NIH Public Access. 2013; 64(10):1431-1446.Search in Google Scholar

15. Jordan KM, Cameron JS, Snaith M et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2007; 46(8):1372-4.10.1093/rheumatology/kem056a17522099Search in Google Scholar

16. HR Jr, Boice JA et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ. 2002; 324(7352):1488-92.10.1136/bmj.324.7352.1488Search in Google Scholar

17. Chen LC, Ashcroft DM. Risk of myocardial infarction associated with selective COX-2 inhibitors: Meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf. 2007; 16(7):762-72.18.10.1002/pds.1409Search in Google Scholar

18. Burns CM, Wortmann RL. Latest evidence on gout management: what the clinician needs to know. Ther Adv Chronic Dis. 2012; 3(6):271-286.10.1177/2040622312462056Search in Google Scholar

19. Hein J, Janssen M, Hvan de Lisdonk E et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008; 371(9627):1854-1860.10.1016/S0140-6736(08)60799-0Search in Google Scholar

20. Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskel Dis. 2016; 8(4):145-159.10.1177/1759720X16646703495962627493693Search in Google Scholar

21. Zhang Y, Neogi T, Chen C et al. Cherry Consumption and the Risk of Recurrent Gout Attacks. Arthritis Rheum. 2012; 64(12):4004-4011.10.1002/art.34677351033023023818Search in Google Scholar

22. Li Q, Li X, Wang J et al. Diagnosis and treatment for hyperuricemia and gout : a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2019; 9:e026677.10.1136/bmjopen-2018-026677672046631446403Search in Google Scholar

23. Vargas-Santos AB, Peloquin CE, Zhang Y, Neogi T. Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment. JAMA Intern Med. 2018; 178(11):1526-1533.10.1001/jamainternmed.2018.4463624819930304329Search in Google Scholar

24. Goicoeche M, García de Vinuesa S, Verdalles U et al. Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk. Clin J Am Soc Nephrol. 2010; 5(8):1388-93.10.2215/CJN.01580210292441720538833Search in Google Scholar

25. Macdonald PA, Eustace D, Palo WA, Streit J et al. Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout. N Engl J Med. 2005; 353:2450-2461.10.1056/NEJMoa05037316339094Search in Google Scholar

26. Avena-Woods C, Hilas O. Febuxostat (Uloric), A New Treatment Option for Gout. Drug Forecast. 2010; 35(2):82-85.Search in Google Scholar

27. Guttmann A, Krasnokutsky S, Pillinger MH, Berhanu A. Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations. Ther Adv Drug Saf. 2017; 8(12):379-388.10.1177/2042098617727714570310129204266Search in Google Scholar